Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, single arm, pivotal Phase 2 trial assessing ALETA-001 in diffuse large B-cell lymphoma (DLBCL) patients

Next Previous
X
Search
Trial Profile

A multi-center, single arm, pivotal Phase 2 trial assessing ALETA-001 in diffuse large B-cell lymphoma (DLBCL) patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALETA-001 (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Aleta Biotherapeutics

    • Most Recent Events

    • 29 Jun 2021 New trial record
    • 23 Jun 2021 According to Aleta Biotherapeutics media release, after the recommended Phase 2 dose of ALETA-001 has been determined, Aleta will initiate this trial which will be designed to support potential accelerated approval of ALETA-001.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top